The Lack of Benefit of a Combination of an Angiotensin Receptor Blocker and Calcium Channel Blocker on Contrast-Induced Nephropathy in Patients with Chronic Kidney Disease

Figures & data

Table 1.  Baseline characteristics of patients.

Variable	AVH group (n = 45)	H group (n = 45)	p-Value
Age (years)	66.38 ± 12.2	62.07 ± 8.77	0.058
Male/female (%)	60/40	66.7/33,3	0.66
BMI (kg/m^2)	27.69 ± 4.29	28.24 ± 3.9	0.52
LVEF (%)	46.16 ± 14.27	49.76 ± 14.99	0.247
Hypertension n (%)	30 (66.7%)	32 (71.1%)	0.82
Diabetes mellitus n (%)	19 (42.2%)	18 (40%)	1.0
History of smoking n (%)	48.9	53.3	0.83
Use of diuretics (%)	22.2	26.7	0.80
Total cholesterol (mg/dL)	179.33 ± 45.15	172.53 ± 49.76	0.49
LDL-C (mg/dL)	112.6 ± 50.26	103.96 ± 37.71	0.35
Hemoglobin (g/dL)	13.91 ± 2.43	14.11 ± 1.82	0.64
Baseline Scre (mg/dL)	1.13 ± 0.33	1.07 ± 0.23	0.31
Baseline eGFR (mL/min)	69.19 ± 24.91	72.01 ± 19.68	0.55
Baseline proteinuria (g/day)	0.19 (0.01–4.44)	0.13 (0–1.7)	0.003*
GFR <60 mL/dk, n (%)	18 (%)	13 (%)	0.37
Contrast amount (mL)	60 (30.0–200)	60 (25.0–250)	0.58
Mehran risk score	7 (0.0–21.0)	6 (0.0–20.0)	0.064
Multivessel involvement in CAG	2 (0.0–4.0)	1 (0.0–3.0)	0.009*

Notes: AVH, amlodipine + valsartan + hydration; H, hydration. Data are expressed as mean ± standard deviation. BMI, body mass index; LVEF, left ventricular ejection fraction; LDL-C, low density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate calculated by MDRD formula; S_cre, serum creatinine.

*p < 0.05.

Table 2.  Post-angiographic changes in renal parameters and CIN incidence in the two groups.

	AVH group	H group	p-Value
Scre (mg/dL)
Baseline	1.13 ± 0.33	1.07 ± 0.23	0.31
Post-procedural	1.18 ± 0.33	1.05 ± 0.23	0.03*
eGFR (mL/min)
Baseline	69.19 ± 24.91	72.01 ± 19.68	0.55
Post-procedural	65.27 ± 22.0	73.44 ± 19.87	0.06
CIN incidence, no. (%)	8 (17.8)	3 (6.7)	0.197
Proteinuria (mg/mg)
Baseline	0.19 (0.01–4.44)	0.13 (0–1.7)	0.003*
Post-procedural	0.16 (0–4.4)	0.14 (0–1.1)	0.16

Notes: Values are mean ± SD.

*p < 0.05.

Figure 1.  CIN incidence of the patient groups.